Martin H. Voss, MD of Memorial Sloan Kettering outlines the DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial at the 2017 Kidney Cancer Association symposium in Miami, FL.
DART Study A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial
